Pervasis Therapeutics, Inc. (Pervasis) is a clinical-stage cell-based biotechnology company, engaged in provision of biologically active cellular therapies for treating vascular and other serious diseases. It has developed a novel, allogeneic endothelial cell therapy for the repair and restorement of vascular function after injury by mimicking the body`s natural healing process. Pervasis is into exploration of broader indications for its groundbreaking technology in non-vascular applications like wound healing and inflammation, bone and joint repair. Recently, the company granted orphan drug designation for its Vascugel, which is in its clinical trail phase. Pervasis is headquartered in Massachusetts, the US.